Evidence map›Paper›PMID 41830981›Full record

ArticleArchives of microbiology2026

Challenging the fitness cost: expression of the cryptic E. coli bgl operon lacks a measurable growth disadvantage in exponential phase.

Kartika Vashishtha, S Mahadevan

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kartika VashishthaDepartment of Developmental Biology and Genetics, Indian Institute of Science, Bangalore, 560012, India. kartikav@alum.iisc.ac.in.
S MahadevanDepartment of Developmental Biology and Genetics, Indian Institute of Science, Bangalore, 560012, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptic genes are phenotypically silent DNA sequences with the potential to code for a function but remain inactive during the normal life span of the organism. However, they can be activated by a single mutational event such as recombination, deletion, insertions or point mutation, resulting in a discernible phenotype. These phenotypes impart a growth advantage to the bacteria under stress and harsh living conditions. The bgl operon of Escherichia coli is involved in the uptake and breakdown of plant-derived aromatic β-glucosides like salicin and arbutin, is one of the well-studied examples of a cryptic genetic system. Previous studies have shown that the activated allele of the operon is beneficial to bacteria under selective conditions such as, survival in long term stationary growth phase, in the presence of predators, and antibiotics. All the observations point towards the possibility of the having a growth disadvantage and therefore a fitness cost associated with the activated operon under nonselective or less stressful conditions. To test the hypothesis the pair-wise competition experiments under nutrient-rich growth conditions using strains of different bgl genotypes were conducted. We report that a strain expressing the bgl operon constitutively, thus bypassing the requirement for a β-glucoside inducer, does not exhibit a measurable growth disadvantage over a strain carrying the wild type (silent or non-activated) bgl locus. These results imply that the classic cost-benefit model of bet-hedging may not be universally applicable and fitness trade-off might be more nuanced, existing only under specific environmental or resource-limited conditions.

Indexed as

Escherichia coliEscherichia coli ProteinsGenetic FitnessOperonArbutinBenzyl AlcoholsGene Expression Regulation, BacterialGlucosidesArbutinBenzyl AlcoholsEscherichia coli ProteinsGlucosidessalicinBglBBglFBglGbgl operonExponential phaseNon-selective conditions

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.